Using HiFi Long-Read Whole Genome Sequencing To Enhance Diagnosis In Patients With Subfertility And/Or Recurrent Pregnancy Loss

This multicenter study demonstrates that PacBio HiFi long-read whole genome sequencing serves as a comprehensive single-test diagnostic tool for couples with unexplained subfertility or recurrent pregnancy loss, identifying clinically significant genetic variants in approximately 10% of cases while characterizing diverse genomic variations.

The Gist

The Big Picture: The "One-Stop Shop" for Genetic Mysteries

Imagine a couple trying to start a family, but they are stuck. They might be struggling to get pregnant (subfertility) or experiencing repeated miscarriages (recurrent pregnancy loss). Often, doctors run a battery of different tests—like checking the chromosomes, looking at specific genes, or scanning for missing pieces of DNA. It's like trying to fix a broken car by checking the engine, then the tires, then the brakes, one by one, hoping to find the problem.

This paper describes a study where researchers tried a new approach: HiFi Long-Read Whole Genome Sequencing.

Think of the human genome (your DNA) as a massive library of instruction manuals.

• Old tests are like trying to read those manuals by looking at tiny, blurry photocopies of just a few pages at a time. You might miss a whole chapter or a typo because the pages are cut up.
• The new test (HiFi Long-Read) is like having a high-definition, continuous video of the entire library. You can see the whole story in one go, including the messy parts where the text folds over itself or repeats.

What Did They Do?

The researchers formed a team across five hospitals in Asia (Singapore, Thailand, Taiwan, and South Korea). They recruited 96 individuals (mostly couples) who had unexplained fertility issues.

They took a blood sample from each person and used the "HiFi" technology to read their entire genetic library in one single, high-quality pass. They didn't just look for one type of error; they looked for everything:

• Single letter typos (SNVs).
• Missing or extra words (Indels).
• Big chunks of text that were rearranged or deleted (Structural Variants).
• Even chemical tags on the DNA that change how the book is read (Methylation).

What Did They Find?

Out of the 84 people who successfully completed the test, the results were promising:

1. Solving the Mystery: In about 1 out of every 10 couples, the test found a clear genetic reason for their struggles.

   • Example: One woman had a specific "typo" in a gene called STAT3 that explained her ovarian issues. Another had a "broken page" in a gene called ERCC6.
   • Before this test, these people had no diagnosis. Now, they have a name for the problem.

2. The "Maybe" Answers: For another 14% of people, the test found genetic changes that might be the cause, but scientists aren't 100% sure yet. These are like finding a suspicious stain in the manual that looks like a typo, but you need more proof to be certain.

3. Ruling Out the Rest: For the people where no cause was found, the test was still useful. It acted like a "clean bill of health" for the genetic side. It told them, "We checked the whole library, and there are no obvious genetic errors here." This helps doctors and patients stop looking for genetic causes and focus on other possibilities (like lifestyle or environmental factors).

4. Bonus Discoveries: Because they read the whole library, they found a few extra things:

   • One person had a genetic clue for high cholesterol (a secondary finding).
   • Several people were "carriers" for recessive diseases (like being a silent passenger of a genetic trait), which is important info for family planning.
   • Crucially, the technology was so good it could tell if two bad "typos" were on the same page or different pages. This helped confirm that one person was just a carrier and not actually sick, saving them from unnecessary worry.

What the Paper Says About the Future

The authors are careful to say that this is a proof-of-concept study. They aren't saying this test should replace all others today.

• The Cost: They admit this test is currently more expensive than the old, piecemeal tests.
• The Limits: They note that while this test is great at reading text, it still struggles to spot certain types of "structural rearrangements" (like a whole chapter being swapped with another book) that traditional microscope tests (karyotyping) are still good at finding. So, for now, patients might still need a mix of old and new tests.
• The Goal: The main takeaway is that this "one-stop shop" approach works. As the technology gets cheaper and the software gets smarter, it could become the first test doctors order, saving couples from a long, frustrating journey of running multiple different tests.

In a Nutshell

This study shows that using a single, high-tech "super-reader" to scan a couple's entire genetic code can find the answer to fertility struggles in about 10% of cases that were previously unsolvable. It's like upgrading from a magnifying glass to a satellite image: you see more, you see it faster, and you get a much clearer picture of the whole landscape.

Technical Summary

Technical Summary: Using HiFi Long-Read Whole Genome Sequencing To Enhance Diagnosis In Patients With Subfertility And/Or Recurrent Pregnancy Loss

Problem Statement
Subfertility and recurrent pregnancy loss (RPL) affect a significant proportion of couples globally, with genetic causes estimated in up to 30% of cases. Current diagnostic workflows are fragmented, relying on sequential testing including conventional karyotyping (limited to large structural rearrangements >5 Mb), chromosomal microarray (CMA), and whole-exome sequencing (WES). These methods fail to detect balanced translocations, inversions, complex chromosomal rearrangements (CCRs), copy number variants (CNVs) in certain contexts, methylation changes, and repeat expansions. Consequently, many couples remain undiagnosed, and the inability to fully characterize genomic variants hinders personalized reproductive counseling and assisted reproductive treatment (e.g., PGT-SR).

Methodology
This multicenter study, conducted by the "HiFi Solves Subfertility Consortium" across five sites in the Asia-Pacific region (Singapore, Thailand, Taiwan, and South Korea), evaluated the utility of Pacific Biosciences (PacBio) HiFi long-read sequencing (LRS) as a unified diagnostic tool.

• Cohort: 96 individuals (47 couples and 2 single females) with unexplained subfertility and/or RPL were recruited. Inclusion criteria required normal karyotypes and the absence of known medical/surgical causes for their conditions.
• Sequencing Protocol: Genomic DNA was sheared to ~15 kb fragments. Libraries were prepared using the SMRTbell® Prep Kit 3.0 and sequenced on the Revio system.
• Bioinformatics Pipeline: A comprehensive PacBio HiFi-human-WGS-WDL pipeline was utilized.
  • Alignment: Reads were aligned to GRCh38 using pbmm2.
  • Variant Calling: SNVs and indels were called via DeepVariant; structural variants (SVs) and CNVs via Sawfish; tandem repeat genotyping via TRGT.
  • Phasing and Specialized Genotyping: Variants were phased using HiPhase. Highly homologous genes (e.g., SMN1/2, HBA1/2, HBB) were analyzed using Paraphase. Epigenetic analysis (5mC) was performed using pb-CpG-tools.
• Variant Prioritization: Candidates were filtered based on depth (≥10x), allele fraction (20–80% for heterozygotes), and frequency (≤1% in gnomAD and in-house cohorts). Variants were annotated using VEP and AnnotSV, prioritized using Phrank scores with Human Phenotype Ontology (HPO) terms, and classified according to ACMG/AMP guidelines.

Key Results

• Data Quality: Of 96 recruited individuals, 84 samples met QC thresholds (mean depth 34.6x, read N50 16.5 kb). The average yield per individual included ~4.1 million SNVs, 855,064 indels, and 38,526 structural variants.
• Diagnostic Yield:
  • Primary Phenotype: 4.8% of individuals (4 out of 84) were identified with likely pathogenic (P/LP) variants explaining their condition.
    • One female carried a pathogenic STAT3 variant associated with autoimmune primary ovarian insufficiency (POI).
    • One female carried a novel frameshift variant in ERCC6 associated with ovarian dysgenesis.
    • Two additional individuals carried variants of uncertain significance (VUS) leaning toward pathogenicity in SOHLH1 and WDR11.
  • Overall Clinical Relevance: Approximately 1 in 10 couples harbored a clinically significant variant when including VUS and secondary findings.
  • Variant Types: The study identified 39 SNVs, 3 indels, and 2 CNVs among prioritized candidates. No pathogenic repeat expansions (including Fragile X) were found.
• Secondary Findings and Carrier Status:
  • One individual (1.4%) had a secondary finding in the LPL gene (hypercholesterolemia).
  • 26 individuals (35.1%) were identified as carriers for at least one recessive genetic disease.
  • Crucially, no couples were found to be carriers for the same recessive disease (except one known couple), and phasing confirmed that a dual-variant individual in DUOX2 was a carrier rather than affected, as both variants were on the same allele.
• Limitations Observed: The study noted that while LRS detects many variant classes, identifying balanced translocations remains challenging due to a lack of normative data for true positive identification; thus, karyotyping remains necessary for this specific indication.

Significance and Claims
The paper claims that HiFi long-read sequencing offers a "unified genomic testing approach" capable of consolidating multiple genetic investigations (SNVs, indels, CNVs, SVs, repeats, and methylation) into a single assay. The study demonstrates that this approach can identify clinically relevant causes in approximately 10% of couples with unexplained subfertility or RPL who have previously undergone conventional testing.

The authors emphasize that LRS provides distinct advantages over short-read sequencing and traditional methods:

1. Comprehensive Detection: It captures a broader spectrum of variant subclasses in one test.
2. Phasing Capability: It allows for the determination of allele phase (cis/trans), which helped rule out compound heterozygosity in specific cases, reducing the need for additional testing.
3. Holistic Insight: It provides data on carrier status and secondary findings, offering broader reproductive and personal health insights beyond the primary phenotype.

The study concludes that while the sample size is modest and the cost of LRS is currently higher than traditional tests, the technology shows significant potential as a first-line comprehensive test. The authors suggest that future studies focusing on cost-effectiveness and larger cohorts will be necessary to optimize care and potentially shift the standard of care toward LRS for these patient populations.